FDA to reclassify surgical staplers as Class II devices requiring premarket review

FDA
Going forward, surgical staplers could fall under special regulatory controls such as mandatory mechanical testing and assessments of their labeling and instructions for use. (Andrew Harnik, Associated Press)

The FDA has proposed to reclassify surgical staplers as higher-risk medical devices—therefore requiring premarket reviews, agency clearance and performance studies—following an increasing number of safety reports in recent years.

Used to stitch together tissues faster than manual suturing, surgical staplers have been categorized as Class I devices since 1988, as part of a group of low-risk “manual surgical instruments for general use.”

By then the staplers had been in common use for many years, and the FDA later exempted manufacturers from premarket notifications. Meanwhile, the internal staples themselves were deemed Class II devices with a moderate level of risk.

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

Going forward, the stapling devices may also be considered Class II hardware—and could fall under special regulatory controls, such as mandatory testing of mechanical features and assessments of their labeling and instructions for correct use, according to the FDA.

An agency review spanning seven years of device reports found more than 32,000 malfunctions, over 9,000 serious injuries and 366 deaths related to surgical staplers. This included misfirings and device failures, as well as malformed staples or reopenings in the wound. User errors were also reported, such as selecting the wrong size cartridge during a procedure. Last month, the FDA notified the industry of these concerns and its intent to take regulatory action.

RELATED: FDA to reevaluate premarket review procedures for surgical staplers

The FDA has also issued a draft guidance (PDF) for manufacturers, offering labeling recommendations covering usage instructions, contraindications, hazards and other safety information. For example, the agency advocated for including warnings against using staples on large blood vessels, and guides on evaluating closure formation and the selection of appropriate staple sizes.

In addition, the FDA plans to receive expert input on its reclassification proposal, as well as the draft guidance, at an advisory panel meeting scheduled for May 30. There the agency plans to present an analysis of all the medical device reports it has received for surgical staplers and their use.

RELATED: FDA chief calls for release of all data tracking problems with medical devices

“Combined, we believe these steps will help better protect patients by ensuring that these devices are safe and effective for their intended use in surgeries,” said the FDA’s Jeffrey Shuren, director of the Center for Devices and Radiological Health, in an agency statement. “We remain dedicated to closely monitoring reports of adverse events associated with surgical staplers for internal use and implanted staples and will take additional action, as needed, to protect patients.”

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.